Imugene (IMU)

Business description

Imugene is an immune oncology company developing HER-Vaxx, a proprietary HER2 +ve cancer vaccine. A Ph Ib dose study is planned in gastric cancer starting in mid-2016 with a direct Ph II follow-on study in 68 patients.

Termination of coverage

Update | Pharmaceutical & healthcare | 21/09/2016

Edison Investment Research is terminating coverage on Imugene (IMU). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news

Imugene

Wed, 28 Oct 2015 04:00:21 GMT

Imugene

Thu, 27 Aug 2015 07:40:18 GMT

Imugene

Mon, 22 Aug 2016 04:02:15 GMT

Imugene

Fri, 01 Sep 2017 07:11:38 GMT

Imugene

Fri, 07 Apr 2017 00:45:00 GMT